Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.50 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942794 | 0.88 | TEAD1 (0.52) | TEAD1TEAD3GPR119HPGDCHEK2 | |
| SCHEMBL3776957 | 0.87 | TEAD1 (0.49) | TEAD1TEAD3GPR119KMT2APLA2G4B | |
| SCHEMBL16385072 | 0.82 | GPR119 (0.67) | TEAD1TEAD3GPR119CHEK2PKM | |
| SCHEMBL833819 | 0.79 | PKM (0.61) | PKMMAPK1TP53TSHRMEN1 | |
| SCHEMBL942754 | 0.78 | HRH2 (0.50) | TEAD1TEAD3GPR119MAPK1 | |
| SCHEMBL946689 | 0.77 | GPR119 (0.45) | TEAD1TEAD3GPR119CHEK2 | |
| SCHEMBL1575733 | 0.77 | GPR119 (0.72) | GPR119CHEK2PKM | |
| SCHEMBL7316232 | 0.76 | NFE2L2 (0.62) | HPGDPKMMAPK1TP53TSHR | |
| SCHEMBL2791601 | 0.75 | SRD5A2 (0.67) | TEAD1TEAD3TSHRMEN1KMT2A | |
| SCHEMBL28802165 | 0.74 | TEAD1 (0.55) | TEAD1TEAD3GPR119HPGDCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003856-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| EP-2146952-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008101885-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003856-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | TEAD1 3553/4885TEAD3 4370/4885GPR119 453/4885 |
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | TEAD1 3553/4885TEAD3 4370/4885GPR119 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.